Investigator financial disclosure prior to Phase III trials urged at FDA workshop.
This article was originally published in The Tan Sheet
Executive Summary
FINANCIAL DISCLOSURE BY INVESTIGATORS PRIOR TO PHASE III efficacy studies should be required by FDA, Association of American Medical Colleges Committee on Research Integrity member David Blake, PhD, urged FDA at a July 20 meeting on the agency's proposed investigator financial disclosure regulation. Blake argued that "to be effective, disclosure and management of possible conflicts must occur before research is undertaken." He added that "FDA's approach...presents both ethical and financial concerns."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning